Amino Allyl MessageAmp™ II aRNA Amplification Kit
Invitrogen™

Amino Allyl MessageAmp™ II aRNA Amplification Kit

Das Amino Allyl II MessageAmp™ aRNA-Amplifikations-Kit enthält Reagenzien für die aRNA-Amplifikation mit Amino-Allyl-NTP-Integration. Das Kit enthält genügend Reagenzien für 20Weitere Informationen
Have Questions?
KatalognummerMenge
AM175320 Reaktionen
Katalognummer AM1753
Preis (EUR)
3.735,00
Each
Menge:
20 Reaktionen
Preis (EUR)
3.735,00
Each
Das Amino Allyl II MessageAmp™ aRNA-Amplifikations-Kit enthält Reagenzien für die aRNA-Amplifikation mit Amino-Allyl-NTP-Integration. Das Kit enthält genügend Reagenzien für 20 Reaktionen. Cy™ Farbstoffe sind nicht enthalten.

Verbesserte cDNA-Synthese des ersten und zweiten Stranges
Im Kit enthalten ist ArrayScript™ RT, eine rational konstruierte M-MLV reverse Transkriptase, die im Vergleich zu anderen Enzymen gleichwertige oder höhere Erträge an cDNA in voller Länge generiert. Die cDNA-Synthesereaktion des zweiten Stranges wurde ebenfalls optimiert, um eine Kompatibilität mit den mit ArrayScript™ RT generierten Erststrang-cDNA-Produkten zu gewährleisten und so die maximale Umwandlung von Erststrang-cDNA in doppelsträngige cDNA-Templates in voller Länge zu ermöglichen.

Verbesserte Markierungseffizienz Ihrer aRNA
Das Amino Allyl MessageAmp™ II aRNA-Amplifikations-Kit integriert Amino-Allyl-NTP in die aRNA, gefolgt von der Kopplung der reaktiven Aminogruppe an eine NHS-Ester-Markierung (z. B. Cy™ oder ein anderer Farbstoff). Diese Strategie bietet gegenüber der direkten Einbindung markierter NTPs mehrere Vorteile. Die direkte Einbindung markierter NTPs ist ineffizient und führt zu niedrigen Erträgen, aRNA mit geringer spezifischer Aktivität und hohen Kosten. Im Gegensatz zu markierten NTPs werden Aminoallyl–modifizierte NTPs fast genauso effizient wie unmodifizierte NTPs integriert und sind wesentlich kostengünstiger als die farbstoffgekoppelten NTPs.
Nur für Forschungszwecke. Nicht zur Verwendung bei diagnostischen Verfahren.
Specifications
Mit Marker oder FarbstoffNein
MarkierungsmethodeIndirekte Markierung
ProduktlinieAmbion, MessageAmp
ProdukttypaRNA-Amplifikationskit
Menge20 Reaktionen
Reverse TranskriptaseArrayScript™
ProbentypPoly(A+) RNA, Gesamt-RNA
FormatKit
Unit SizeEach
Inhalt und Lagerung
• 60 µl T7-Oligo(dT)-Primer (-20 °C)
• 22 µl ArrayScript™ reverse Transkriptase (-20 °C)
• 22 µl RNase-Inhibitor (-20 °C)
• 42 µl 10x Erststrang-Puffer (-20 °C)
• 170 µl dNTP-Gemisch (-20 °C)
• 210 µl 10x Zweitstrang-Puffer (-20 °C)
• 42 µl DNA-Polymerase (-20 °C)
• 22 µl RNase H (-20 °C)
• 84 µl T7-Enzymgemisch (-20 °C)
• 84 µl 10x Reaktionspuffer (-20 °C)
• 95 µl 50 mM-UTP-Lösung (-20 °C)
• 64 µl 50 mM-5-(3-Amino-Allyl)-UTP (-20 °C)
• 255 µl ATP-, CTP-, GTP-Gemisch (-20 °C)
• 40 µl Zweitzyklus-Primer (-20 °C)
• 10 µl 1 mg/ml-Kontroll-RNA (-20 °C)
• 1,75 ml nukleasefreies Wasser (beliebige Temperatur)
• 400 µl Kopplungspuffer (-20 °C)
• 440 µl DMSO (-20 °C)
• 180 µl 4 M-Hydroxylamin (-20 °C)
• 40 ml Waschpuffer (+4 °C oder Raumtemperatur)
• 7 ml cDNA-Bindungspuffer (Raumtemperatur)
• 20 ml aRNA-Bindungspuffer (Raumtemperatur)
• 20 aRNA-Filterkassetten (Raumtemperatur)
• 40 aRNA-Entnahmeröhrchen (Raumtemperatur)
• 20 cDNA-Filterkassetten und -röhrchen (Raumtemperatur)
• 20 cDNA-Elutionsröhrchen (Raumtemperatur)
• 10 ml nukleasefreies Wasser (beliebige Temperatur)
• 20 Filterkassetten und -röhrchen mit markierter aRNA (Raumtemperatur)
• 20 Elutionsröhrchen mit markierter aRNA (Raumtemperatur)

Häufig gestellte Fragen (FAQ)

What is the typical size range of amplified RNA?

A single round of amplification yields product sizes ranging from 200 bases to 6 kb. The majority of these products are approximately 1.5 kb in length. A second round of amplification will result in shorter products. We recommend using an Agilent 2100 bioanalyzer to visualize these products. Amplification products can be visualized by agarose gel electrophoresis; they will migrate as a smear. Although this data is still useful, it is less informative than bioanalyzer analysis.

Find additional tips, troubleshooting help, and resources within our Epigenetics Support Center.

How do direct and indirect labeling of aRNA differ?

Direct labeling is incorporation of modified NTPs into amplification products during the IVT step of the amplification process. To make aRNA that is labeled with fluorescent dyes, a mixture of dye-modified and unmodified (or unlabeled) nucleotides are typically used in order to obtain an optimal ratio of dye-labeled to unlabeled nucleotide for maximal fluorescence. Usually ~200-400 µM of dye-labeled CTP is used with 1-3 mM unlabeled NTPs. Biotin-modified nucleotides are incorporated fairly well with T7 RNA polymerase. We recommend that you use UTP:biotin-UTP ratios of 1:1 to 3:1. In general, labeled nucleotides are not incorporated as efficiently as unlabeled molecules during amplification, and therefore direct labeling does compromise sample yield. Furthermore, if both Cy5 and Cy3 are used in a direct labeling reaction, Cy5 is not incorporated as well as Cy3, and corrections during data analysis are necessary to adjust for this disparity.

Indirect labeling incorporates amino allyl UTP into amplification products during the IVT, and the amino allyl-modified aRNA produced is then chemically coupled to a detectable moiety such as a fluorescent dye or biotin. This method, though more time-consuming than direct labeling, can result in very highly labeled aRNA because amino allyl-modified UTP is incorporated very efficiently by T7 RNA polymerase.

Find additional tips, troubleshooting help, and resources within our Epigenetics Support Center.

Why is RNA amplification necessary?

Glass microarray analysis experiments typically require 5-20 µg of total RNA per slide for sample labeling and hybridization. Thus, microarray-based gene expression analysis of very small samples [laser capture microdissection (LCM), tissue biopsies, or other clinical samples] is difficult due to the very low amounts of total RNA recovered from the samples. Linear amplification of RNA from small samples produces sufficient quantities of RNA for sample labeling and hybridization. Since the amplification technique is highly reproducible and maintains representation of the gene expression in the original sample, it is recommended for probe synthesis by most manufacturers of commercially available microarrays.

Find additional tips, troubleshooting help, and resources within our Epigenetics Support Center.

How is fold amplification calculated?

RNA amplification using the Van Gelder and Eberwine technique (Van Gelder 1990) utilizes an oligo(dT) primer containing the T7 RNA polymerase promoter for synthesis of first strand cDNA. The poly(A) tail at the end of mRNA sequences serves as the substrate for the binding of these primers. Since mRNA typically constitutes only 1-5% of the total RNA in the cell, only this fraction of the total RNA is amplified. The tissue type, its developmental state, and its health all influence the actual proportion of mRNA in a total RNA sample. Total RNA from brain, testes, and embryonic tissues may contain up to 4% mRNA, while RNA from many other tissues will have only 1% or less mRNA. The RNA isolation method can also influence mRNA content. The generally accepted average value for mRNA content is about 2% of a total RNA sample. When 1 µg of total RNA, 2% or 20 ng of which is mRNA, is amplified 1000-fold, yields of 20 µg aRNA (or cRNA) should be expected. You may observe higher fold amplification when starting with lower amounts of total RNA. This is because, in an in vitro transcription (IVT) reaction, a finite amount of RNA can be synthesized with the fixed amount of NTPs. When starting with less RNA, NTPs do not become limiting until the RNA is amplified beyond the typical 1000-2000 fold amplification levels seen with higher amounts of input RNA.

Find additional tips, troubleshooting help, and resources within our Epigenetics Support Center.